---
title: "Mineralys director Brian Taylor Slingsby disposes of 104,320 common shares for $3 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300091813.md"
description: "Mineralys Therapeutics director Brian Taylor Slingsby sold 104,320 common shares on September 22, 2026, for approximately $3 million at a price of $28.8085 per share. Following the transaction, his indirect holdings decreased to 7,805,718 shares. The disclosure was filed via EDGAR."
datetime: "2026-09-25T01:50:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300091813.md)
  - [en](https://longbridge.com/en/news/300091813.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300091813.md)
generator: "portal-rs"
---

# Mineralys director Brian Taylor Slingsby disposes of 104,320 common shares for $3 million

-   Mineralys Therapeutics director Brian Taylor Slingsby disclosed a sale of 104,320 common shares on Sep. 22, 2026. \* Transaction price was USD 28.8085 per share. \* Indirect holdings stood at 7,805,718 shares following the sale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001963901-26-000003), on September 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MLYS.US](https://longbridge.com/en/quote/MLYS.US.md)

## Related News & Research

- [Mineralys Therapeutics CEO Jon Congleton disposes of $1,909,665 common shares](https://longbridge.com/en/news/300830702.md)
- [Will AHA Trial Data Change Mineralys Therapeutics (MLYS) Narrative](https://longbridge.com/en/news/300872529.md)
- [Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026](https://longbridge.com/en/news/300722541.md)
- [Michael Burry Raises Red Flag on Oracle’s $664B Backlog and AI Spending: ‘The Customer Is Now the Lender’](https://longbridge.com/en/news/300913488.md)
- [Can CoreWeave Stock Rally 180%? CRWV Gets Wall Street-High $250 Price Target](https://longbridge.com/en/news/300948858.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**